Načítá se...
Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials
A primary goal of a phase II dose-ranging trial is to identify a correct dose before moving forward to a phase III confirmatory trial. A correct dose is one that is actually better than control. A popular model in phase II is an independent model that puts no structure on the dose-response relations...
Uloženo v:
| Vydáno v: | Stat Med |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6606375/ https://ncbi.nlm.nih.gov/pubmed/31070807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.8167 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|